Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -21.42
- Piotroski Score 1.00
- Grade Buy
- Symbol (BTAI)
- Company BioXcel Therapeutics, Inc.
- Price $0.51
- Changes Percentage (-11.5%)
- Change -$0.07
- Day Low $0.50
- Day High $0.55
- Year High $4.17
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $25.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.18
- Trailing P/E Ratio -0.27
- Forward P/E Ratio -0.27
- P/E Growth -0.27
- Net Income $-179,053,000
Income Statement
Quarterly
Annual
Latest News of BTAI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Hacker obtains House ethics testimony on Matt Gaetz as Trump makes calls for AG nominee
Caroline Downey and Lucy Caldwell discussed the media scrutiny on a former presidential candidate. David French believes the economy and border issues led to the president-elect's victory. Biden's app...
By Fox News | 2 days ago -
Lawyer breaks down Diddy's 'only real chance' in sex crimes trial after feds obtain jailhouse notes
Sean 'Diddy' Combs' defense claims of jail cell search violation are considered weak by legal experts. Facing sex trafficking charges, Combs' legal team argues for attorney-client privilege protection...
By Fox News | 2 days ago -
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...
Rescue medications are allowed in the SERENITY study as a safety measure to track inefficacy for patients on placebo. FDA feedback on the TRANQUILITY trial protocol was deemed satisfactory. The compan...
By Yahoo! Finance | 1 week ago
